Show simple item record

dc.contributor.authorOkines, A. F. C.en
dc.contributor.authorBraybrooke, J.en
dc.contributor.authorMacPherson, I. R.en
dc.contributor.authorSutherland, S.en
dc.contributor.authorHowell, Sacha Jen
dc.contributor.authorWheatley, D.en
dc.contributor.authorWaters, S.en
dc.contributor.authorRoylance, R.en
dc.contributor.authorBaird, R. D.en
dc.contributor.authorOikonomidou, O.en
dc.contributor.authorPalmieri, C.en
dc.contributor.authorHarries, M.en
dc.contributor.authorHarper-Wynne, C.en
dc.contributor.authorSheri, A.en
dc.contributor.authorKhan, S.en
dc.contributor.authorBunce, C.en
dc.contributor.authorMohammed, K.en
dc.contributor.authorLee, D.en
dc.contributor.authorTurner, N. C.en
dc.date.accessioned2023-10-25T08:48:39Z
dc.date.available2023-10-25T08:48:39Z
dc.date.issued2023en
dc.identifier.citationOkines AFC, Braybrooke J, MacPherson IR, Sutherland S, Howell SJ, Wheatley D, et al. Randomised open-label phase II study of induction standard of care fulvestrant and CDK4/ 6 inhibition with addition of ipatasertib in metastatic ER+/HER2-breast cancer patients without circulating tumour (ct) DNA suppression (FAIM). Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772005533.en
dc.identifier.doi10.1200/JCO.2023.41.16_suppl.TPS1111en
dc.identifier.urihttp://hdl.handle.net/10541/626668
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2023.41.16_suppl.TPS1111en
dc.titleRandomised open-label phase II study of induction standard of care fulvestrant and CDK4/ 6 inhibition with addition of ipatasertib in metastatic ER+/HER2-breast cancer patients without circulating tumour (ct) DNA suppression (FAIM)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentThe Royal Marsden NHS Foundation Trust, Londonen
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record